Spago Nanomedical

Spago Nanomedical AB (publ) meddelar idag att ett abstract som beskriver den pågående kliniska fas I/IIa-studien Tumorad-01 med den radiofarmaceutiska läkemedelskandidaten ¹⁷⁷Lu-SN201 har accepterats

Spago Nanomedical AB (publ) today announced that an abstract describing the ongoing Phase I/IIa clinical study Tumorad-01 with the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 has been accepted for

DNB Carnegie has published a new flash comment on Spago Nanomedical following recent news flow. To access the full report and subscribe to future updates, visit https://access.dnbcarnegie.com/companie

Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical phase I/IIa study Tumorad-01 with the drug candidate [177]Lu-SN201

Spago Nanomedical AB (publ) meddelar idag att den oberoende monitoreringskommittén (Data Monitoring Committee, DMC) rekommenderar att den pågående kliniska fas I/IIa-studien Tumorad-01 med läkemedelsk

Spago Nanomedical AB (publ) meddelar idag att Torsten Malmström har tillträtt som Director CMC & Supply. Torsten Malmström ingår även i bolagets ledningsgrupp, vilket ytterligare stärker Spago Nanomed

Spago Nanomedical AB (publ) announced today that Torsten Malmström has assumed the position of Director CMC & Supply. Torsten Malmström also joins the company’s Management Team, further strengthening

DNB Carnegie has published a new commissioned research report on Spago Nanomedical To access the full report and subscribe to future updates, visit https://access.dnbcarnegie.com/companies/1438 Inform

OKTOBER – DECEMBER I SAMMANDRAGNettoomsättningen för kvartalet uppgick till 4 KSEK (617 KSEK) Resultatet för kvartalet uppgick till -5 890 KSEK (-7 830 KSEK) Rörelsens kostnader för kvartalet uppgick

OCTOBER – DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 4 (KSEK 617) The loss for the quarter amounted to KSEK –5,890 (KSEK -7,830) Operating expenses for the quarter amounted to KSEK -6

Last Wednesday, Redeye hosted a Fight Cancer 2026 theme event. The global fight against cancer remains a primary focus area for the life sciences industry. It was an exclusive event featuring leading

This Wednesday, between 09:00-15:50, Redeye will host a Fight Cancer 2026 theme event. The global fight against cancer remains a primary focus area for the life sciences industry. Join us for an exclu

I enlighet med instruktionen för valberedningen, som beslutades av årsstämman, har en valberedning utsetts inför årsstämman 2026. Valberedningen inför årsstämman 2026 har utsetts baserat på de största

In accordance with the instructions to the nomination committee resolved by the Annual General Meeting (“AGM”), a nomination committee for the 2026 AGM has been appointed. The nomination committee for

NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFR

EJ AVSEDD FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER